Pk-11195

Pk-11195

SCHEMBL117124

CCC(C)N(C)C(=O)c1cc2ccccc2c(-c2ccccc2Cl)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TSPO P30536 7/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2C9 P11712 1/20 1.00
TSHR P16473 1/20 1.00
ALDH1A1 P00352 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
NR1I3 Q14994 1/20 1.00
NPSR1 Q6W5P4 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(R)Pk-11195 SCHEMBL15118334 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
(R)Pk-11195 SCHEMBL7685386 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
(R)Pk-11195 SCHEMBL29357086 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
(R)Pk-11195 SCHEMBL12790424 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
Pk-11195 SCHEMBL29354252 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
(R)Pk-11195 SCHEMBL3126094 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
(R)Pk-11195 SCHEMBL29477174 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
Pk-11195 SCHEMBL31060347 1.00 TSPO (1.00) TSPOMEN1KMT2ACYP3A4CYP2C9
SCHEMBL3046732 0.89 TSPO (0.81) TSPOMEN1KMT2ACYP3A4CYP2C9
SCHEMBL3035734 0.89 TSPO (0.81) TSPOMEN1KMT2ACYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019067210-A1 COMPOSITIONS AND METHODS FOR TREATING AR-AND/OR LNCRNA-MEDIATED DISEASES DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-04-04 WO claimed
US-20190071668-A1 COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF CANCER USING SLNCR ISOFORMS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-03-07 US claimed
EP-3320093-A2 COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT PREVENTION, AND TREATMENT OF CANCER USING SLNCR ISOFORMS Dana-Farber Cancer Institute, Inc. (US) 2018-05-16 EP claimed
WO-2017007941-A2 COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT PREVENTION, AND TREATMENT OF CANCER USING SLNCR ISOFORMS DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-01-12 WO claimed
US-20160184461-A1 FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-06-30 US claimed
US-20140140932-A1 Functionalized Magnetic Nanoparticles and Use in Imaging Amyloid Deposits and Neurofibrillary Tangles THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-22 US claimed
EP-2699157-A2 FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES The Regents of the University of California (US) 2014-02-26 EP claimed
CN-103491870-A Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles UNIV CALIFORNIA 2014-01-01 CN claimed
EP-1878443-B1 THERAPEUTIC AGENT FOR NEUROPATHIC PAIN JAPAN SCIENCE & TECH AGENCY (JP) 2012-12-12 EP claimed
WO-2012145169-A2 FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-10-26 WO claimed
EP-1077702-A1 PERIPHERAL BENZODIAZEPINE RECEPTOR LIGANDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2001-02-28 EP claimed
WO-2000037086-A1 AGONISTS AND ANTAGONISTS OF PERIPHERAL-TYPE BENZODIAZEPINE RECEPTORS SCIOS INC. (US) 2000-06-29 WO claimed
WO-1999066958-A2 USE OF A COMPOUND HAVING AFFINITY FOR THE BENZODIAZEPINE MITOCHONDRIAL RECEPTOR IN CANCER THERAPY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1999-12-29 WO claimed
CN-1239437-A Mitochondrial membrane stabilizer DAIICHI SEIYAKU CO (JP) 1999-12-22 CN claimed
WO-1999061024-A1 PERIPHERAL BENZODIAZEPINE RECEPTOR LIGANDS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 1999-12-02 WO claimed
EP-0953356-A1 MITOCHONDRIAL MEMBRANE STABILIZER DAIICHI PHARMACEUTICAL CO., LTD. (JP) 1999-11-03 EP claimed
EP-0789567-A4 A METHOD FOR TREATING VASCULAR HEADACHES GEN HOSPITAL CORP (US) 1999-01-13 EP claimed
US-5776946-A Peripheral benzodiazepine receptor ligands as antiinflammatory agents MCGEER, EDITH G. (CA) 1998-07-07 US claimed
EP-0789567-A1 A METHOD FOR TREATING VASCULAR HEADACHES THE GENERAL HOSPITAL CORPORATION (US) 1997-08-20 EP claimed
WO-1996015782-A1 A METHOD FOR TREATING VASCULAR HEADACHES THE GENERAL HOSPITAL CORPORATION (US) 1996-05-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140140932-A1 Functionalized Magnetic Nanoparticles and Use in Imaging Amyloid Deposits and Neurofibrillary Tangles MAPT, PRNP, APP TSPO 91/4885MEN1 293/4885KMT2A 2374/4885
US-20160184461-A1 FUNCTIONALIZED MAGNETIC NANOPARTICLES AND USE IN IMAGING AMYLOID DEPOSITS AND NEUROFIBRILLARY TANGLES MAPT, PRNP, APP TSPO 91/4885MEN1 293/4885KMT2A 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.